- Methohexital injection: Fresenius Kabi is reporting supply issues with the anesthetic. The company expects more availability by mid-October.
- Bacitracin ophthalmic ointment: Akorn Pharmaceuticals, the drug’s sole supplier, has stopped production due to a manufacturing halt.
- Estradiol and norethindrone acetate transdermal system: Novartis is reporting shortages for this hormone replacement therapy. There is no estimated release date for new stock.
- Silver nitrate solution: The sole supplier, Pharmacy Solutions, has experienced manufacturing delays. New supplies are expected to be available in early November.
- Bevacizumab-bvzr injection: Amgen has reported shortages of the oncology drug due to increased demand. The company projects more availability in late October.
- Diphenoxylate hydrochloride and atropine hydrochloride oral solution: Morton Grove Pharmaceuticals is the sole supplier and is experiencing a supply disruption due to packaging issues, with no release date.
- Indocyanine Green injection: The medical dye, which is used to measure cardiac input, liver function and blood flow, is in shortage. Renew Pharmaceuticals has a limited supply of one presentation until December.
- Cyclosporine solution: Novartis pharmaceuticals has discontinued the brand-name version of the solution which is used to prevent organ transplant rejection.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
